Brokerages Set CureVac N.V. (NASDAQ:CVAC) Target Price at $6.83

CureVac N.V. (NASDAQ:CVAC) has earned an average recommendation of “Hold” from the six research firms that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $6.8333.

Separately, Weiss Ratings restated a “hold (c-)” rating on shares of CureVac in a report on Wednesday, October 8th.

CureVac Stock Performance

Shares of CVAC stock opened at $5.34 on Tuesday. CureVac has a 12 month low of $2.37 and a 12 month high of $5.72. The company has a market cap of $1.20 billion, a PE ratio of 5.56 and a beta of 2.51. The company has a quick ratio of 6.16, a current ratio of 6.17 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $5.37 and its two-hundred day moving average is $4.98.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings data on Thursday, August 21st. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.15). CureVac had a return on equity of 29.57% and a net margin of 38.21%.The firm had revenue of $1.41 million for the quarter, compared to the consensus estimate of $4.27 million. Equities analysts predict that CureVac will post 0.72 EPS for the current year.

Institutional Trading of CureVac

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CureVac by 354.8% during the second quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock worth $30,000 after buying an additional 4,375 shares during the last quarter. Headlands Technologies LLC bought a new position in CureVac during the second quarter worth $35,000. Greenleaf Trust acquired a new position in CureVac during the 1st quarter valued at $31,000. Kathmere Capital Management LLC acquired a new position in CureVac during the 2nd quarter valued at $60,000. Finally, L2 Asset Management LLC bought a new stake in CureVac in the 2nd quarter valued at $70,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.